GSK2018682

Cat. No.: HY-19511

CAS No.: 1034688-30-6

Molecular Formula: $C_{22}H_{21}ClN_4O_4$

Molecular Weight: 440.88

Target: LPL Receptor

Pathway: GPCR/G Protein

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 125 mg/mL (283.52 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.2682 mL	11.3410 mL	22.6819 mL
5 mM	0.4536 mL	2.2682 mL	4.5364 mL
10 mM	0.2268 mL	1.1341 mL	2.2682 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.72 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.08 mg/mL (4.72 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.72 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC_{50}s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.

IC_{50} & Target

pEC50: 7.7 (S1P1 receptor), 7.2 (S1P5 receptor)[1]

In Vitro

GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC_{50}s of 7.7 and 7.2, respectively, and has no agonist activity

towards human S1P2, S1P3, or S1P4[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Xu J, et al. Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers. Clin Pharmacol Drug Dev. 2014 May;3(3):170-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA